Capricor Therapeutics (US.CAPR)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.CAPR · 同比： 2026 Q1 vs 2025 Q1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 136.7% | ↑ |
| ROE | -12.2% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.05 | ↓ |
| Gross Margin | - | → |
US.CAPR (Capricor Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 136.7% ↑ ROE -12.2% ↑ Cash Conversion - → D/E Ratio 0.05 ↓ Gross Margin - →
核心指标
US.CAPR (Capricor Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 136.7% ↑ROE -12.2% ↑Cash Conversion - →D/E Ratio 0.05 ↓Gross Margin - →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies